125 related articles for article (PubMed ID: 38101608)
1. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
Yang Y; Wang J; Wang J; Zhao X; Zhang T; Yang Y; Pang J; Ou Q; Wu L; Xu X; Xu K; Zhao J; Bai N; Yang P; Wang S; Wang L; Bi N
Cancer Lett; 2024 Feb; 582():216569. PubMed ID: 38101608
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
[TBL] [Abstract][Full Text] [Related]
3. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
5. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
6. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection.
Provencio M; Majem M; Guirado M; Massuti B; de Las Peñas R; Ortega AL; Dómine M; Marsé R; Sala MÁ; Paredes A; Morán T; Vázquez S; Coves J; Larriba JLG; Sánchez JM; Vicente D; Farré N; Fornos LF; Zapata I; Franco F; Serna-Blasco R; Romero A; Isla D
Lung Cancer; 2021 Mar; 153():25-34. PubMed ID: 33453470
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
9. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
Pan Y; Zhang JT; Gao X; Chen ZY; Yan B; Tan PX; Yang XR; Gao W; Gong Y; Tian Z; Liu SM; Lin H; Sun H; Huang J; Liu SY; Yan HH; Dong S; Xu CR; Chen HJ; Wang Z; Li P; Guan Y; Wang BC; Yang JJ; Tu HY; Yang XN; Zhong WZ; Xia X; Yi X; Zhou Q; Wu YL
Cancer Cell; 2023 Oct; 41(10):1763-1773.e4. PubMed ID: 37816331
[TBL] [Abstract][Full Text] [Related]
10. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
Wang Y; Zhang T; Wang J; Zhou Z; Liu W; Xiao Z; Deng L; Feng Q; Wang X; Lv J; Ma X; Xue Q; Wang J; Wang Z; Bi N
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):590-600. PubMed ID: 36623605
[TBL] [Abstract][Full Text] [Related]
11. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
[TBL] [Abstract][Full Text] [Related]
12. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
Lebow ES; Shaverdian N; Eichholz JE; Kratochvil LB; McCune M; Murciano-Goroff YR; Jee J; Eng J; Chaft JE; Kris MG; Kalashnikova E; Feeney J; Scalise CB; Sudhaman S; Palsuledesai CC; Malhotra M; Krainock M; Sethi H; Aleshin A; Liu MC; Shepherd AF; Wu AJ; Simone CB; Gelblum DY; Johnson KA; Rudin CM; Gomez DR; Razavi P; Reis-Filho JS; Isbell JM; Li BT; Rimner A
Front Oncol; 2023; 13():1253629. PubMed ID: 37795442
[TBL] [Abstract][Full Text] [Related]
13. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: A meta-analysis and systematic review.
Hung MS; Wu YF; Chen YC
Medicine (Baltimore); 2019 Jul; 98(27):e16167. PubMed ID: 31277121
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study.
Guan S; Ren K; Zhang X; Yan M; Li X; Zhao L
Radiat Oncol; 2023 Jul; 18(1):122. PubMed ID: 37491257
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Fan G; Zhang K; Ding J; Li J
Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
[TBL] [Abstract][Full Text] [Related]
18. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
[TBL] [Abstract][Full Text] [Related]
19. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis.
Wang X; Ding X; Kong D; Zhang L; Guo Y; Ren J; Hu X; Yang J; Gao S
Int J Clin Oncol; 2017 Apr; 22(2):229-236. PubMed ID: 28005209
[TBL] [Abstract][Full Text] [Related]
20. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy].
Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339
[No Abstract] [Full Text] [Related]
[Next] [New Search]
